Hudson Bay Capital Management
ABOS icon

Hudson Bay Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Hudson Bay Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
968,940
+243,940
+34% +$622K 0.01% 736
2025
Q4 		$1.53M Sell
725,000
-4
-0% -$8 0.01% 748
2025
Q3 		$1.24M Sell
725,004
-100,000
-12% -$138K ﹤0.01% 829
2025
Q2 		$957K Buy
825,004
+55,004
+7% +$59.1K ﹤0.01% 968
2025
Q1 		$847K Buy
770,000
+55,000
+8% +$78.6K ﹤0.01% 952
2024
Q4 		$1.23M Buy
715,000
+79,000
+12% +$190K ﹤0.01% 717
2024
Q3 		$1.58M Sell
636,000
-34,000
-5% -$92.2K 0.01% 599
2024
Q2 		$1.62M Buy
670,000
+110,000
+20% +$350K 0.01% 548
2024
Q1 		$2.27M Sell
560,000
-4,400
-0.8% -$16.6K 0.01% 432
2023
Q4 		$2.17M Buy
564,400
+39,400
+8% +$117K 0.01% 436
2023
Q3 		$2.18M Buy
525,000
+130,000
+33% +$803K 0.02% 460
2023
Q2 		$1.9M Buy
395,000
+38,000
+11% +$182K 0.01% 513
2023
Q1 		$1.45M Buy
357,000
+117,000
+49% +$611K 0.01% 557
2022
Q4 		$1.3M Buy
+240,000
New +$1.61M 0.01% 665

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Hudson Bay Capital Management's ABOS Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Acumen Pharmaceuticals (ABOS) stake by 34% in Q1 2026, buying an estimated $622K and bringing the position to 968,940 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #736.

Hudson Bay Capital Management first reported a position in ABOS in Q4 2022 and has held it in 14 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Hudson Bay Capital Management held 968,940 shares of Acumen Pharmaceuticals worth $2.29M as of Q1 2026.
  • Hudson Bay Capital Management bought 243,940 Acumen Pharmaceuticals shares in Q1 2026, an estimated $622K.
  • Acumen Pharmaceuticals made up 0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #736 holding.
  • Hudson Bay Capital Management first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.